These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 33255582)

  • 1. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
    Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
    Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
    Front Immunol; 2019; 10():910. PubMed ID: 31105707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells.
    Munari E; Quatrini L; Ciancaglini C; Eccher A; Bogina G; Moretta L; Mariotti FR
    Semin Immunol; 2022 Nov; 61-64():101660. PubMed ID: 36370672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
    Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
    Front Immunol; 2019; 10():1242. PubMed ID: 31214193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
    Buckle I; Guillerey C
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cell Dysfunction and Checkpoint Immunotherapy.
    Bi J; Tian Z
    Front Immunol; 2019; 10():1999. PubMed ID: 31552017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
    Sun H; Sun C
    Front Immunol; 2019; 10():2354. PubMed ID: 31681269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helper-like innate lymphoid cells and cancer immunotherapy.
    Crinier A; Vivier E; Bléry M
    Semin Immunol; 2019 Feb; 41():101274. PubMed ID: 31072659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helper Innate Lymphoid Cells-Unappreciated Players in Melanoma Therapy.
    Garofalo C; Cerantonio A; Muscoli C; Mollace V; Viglietto G; De Marco C; Cristiani CM
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cells and anti-tumor immunity.
    Nicholson SE; Keating N; Belz GT
    Mol Immunol; 2019 Jun; 110():40-47. PubMed ID: 29233542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy.
    Cazzetta V; Depierreux D; Colucci F; Mikulak J; Mavilio D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.
    Zaghi E; Calvi M; Marcenaro E; Mavilio D; Di Vito C
    J Leukoc Biol; 2019 Jun; 105(6):1243-1251. PubMed ID: 30645023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
    Knaus HA; Kanakry CG; Luznik L; Gojo I
    Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.
    Noel ODV; Hassouneh Z; Svatek RS; Mukherjee N
    Cancer Immunol Res; 2024 Feb; 12(2):149-160. PubMed ID: 38060011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.